Hosted on MSN
Relmada signals 2026 launch of two pivotal studies for NDV-01 and sepranolone, supported by $100M financing
CEO Sergio Traversa highlighted a "standout year" for Relmada, citing "excellent product development progress" and a "recent successful capital raise." He emphasized the advancement of two clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results